Nilotinib Zentiva

Nilotinib, the active ingredient in Nilotinib Zentiva, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It treats chronic myeloid leukemia and related BCR‑ABL positive leukemias in adult patients. The medication is approved in the European Union and is administered under medical supervision.

GNH USA supplies Nilotinib Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. Our distribution network ensures timely delivery and compliance with local regulatory requirements. We adhere to stringent quality standards throughout the supply chain.

Nilotinib is a targeted therapy that inhibits the BCR‑ABL tyrosine kinase pathway in certain leukemias.

Chronic myeloid leukemia (CML): reduces disease progression and improves survival in patients with BCR‑ABL positive disease. Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): used in combination with chemotherapy to achieve remission. CML in accelerated phase: provides disease control when resistance to prior therapy occurs. CML in blast crisis: may be used as part of a multi‑agent regimen to reduce leukemic burden.

Nilotinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Diarrhea - Rash - Fatigue

Serious or Rare Side Effects: - QT interval prolongation or cardiac arrhythmias - Severe liver injury (hepatitis) - Pancreatitis

Nilotinib requires careful monitoring and specific safety measures. - Cardiac monitoring: assess ECG and correct electrolyte imbalances before and during therapy. - Liver function: perform baseline and periodic liver enzyme tests. - Blood glucose: monitor for hyperglycemia, especially in diabetic patients. - Drug interactions: avoid concomitant use of strong CYP3A4 inhibitors. - Store at room temperature: keep in the original container, protect from moisture and light.

Nilotinib can interact with several medicines, affecting its safety and effectiveness.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nilotinib plasma levels. - QT‑prolonging agents (e.g., amiodarone, sotalol): raise risk of cardiac arrhythmias. - Antacids containing aluminum or magnesium: reduce nilotinib absorption.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole): may modestly raise drug exposure. - Warfarin: may require INR monitoring due to potential interaction.